Cargando…
Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience
BACKGROUND: Imatinib mesylate is the cornerstone therapy in the management of chronic myeloid leukemia (CML). Monitoring of adverse drug reactions (ADRs) of imatinib in our patients is very important to ensure their safety. Aims and Objectives: The current study aims to monitor ADRs encountered in C...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846910/ https://www.ncbi.nlm.nih.gov/pubmed/36537404 http://dx.doi.org/10.4103/ijp.ijp_844_21 |
_version_ | 1784871306141892608 |
---|---|
author | Swain, Trupti Rekha Goutam, Siddhartha Jena, Rabindra Kumar Rout, Niranjan |
author_facet | Swain, Trupti Rekha Goutam, Siddhartha Jena, Rabindra Kumar Rout, Niranjan |
author_sort | Swain, Trupti Rekha |
collection | PubMed |
description | BACKGROUND: Imatinib mesylate is the cornerstone therapy in the management of chronic myeloid leukemia (CML). Monitoring of adverse drug reactions (ADRs) of imatinib in our patients is very important to ensure their safety. Aims and Objectives: The current study aims to monitor ADRs encountered in CML patients in the chronic phase with imatinib (400 mg/day). MATERIALS AND METHODS: This prospective, observational study was conducted from November 2011 to May 2015 on 310 patients presented to the Departments of Clinical Hematology and Pharmacology of SCB MCH, Cuttack, diagnosed with CML at chronic phase. Collected ADRs were entered in the ADR reporting form (PvPI) and were analyzed for causality and severity. RESULTS: Anemia was the most common hematological ADR, whereas hyperpigmentation and nausea were the most common nonhematological ADRs reported. Maximum ADRs were mild to moderate and required no change in the treatment course. CONCLUSION: The study revealed that imatinib mesylate, a well tolerated drug, has very few cases of severe ADRs in Indian patients at the chronic stable phase of CML. |
format | Online Article Text |
id | pubmed-9846910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-98469102023-01-19 Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience Swain, Trupti Rekha Goutam, Siddhartha Jena, Rabindra Kumar Rout, Niranjan Indian J Pharmacol Short Communication BACKGROUND: Imatinib mesylate is the cornerstone therapy in the management of chronic myeloid leukemia (CML). Monitoring of adverse drug reactions (ADRs) of imatinib in our patients is very important to ensure their safety. Aims and Objectives: The current study aims to monitor ADRs encountered in CML patients in the chronic phase with imatinib (400 mg/day). MATERIALS AND METHODS: This prospective, observational study was conducted from November 2011 to May 2015 on 310 patients presented to the Departments of Clinical Hematology and Pharmacology of SCB MCH, Cuttack, diagnosed with CML at chronic phase. Collected ADRs were entered in the ADR reporting form (PvPI) and were analyzed for causality and severity. RESULTS: Anemia was the most common hematological ADR, whereas hyperpigmentation and nausea were the most common nonhematological ADRs reported. Maximum ADRs were mild to moderate and required no change in the treatment course. CONCLUSION: The study revealed that imatinib mesylate, a well tolerated drug, has very few cases of severe ADRs in Indian patients at the chronic stable phase of CML. Wolters Kluwer - Medknow 2022 2022-12-13 /pmc/articles/PMC9846910/ /pubmed/36537404 http://dx.doi.org/10.4103/ijp.ijp_844_21 Text en Copyright: © 2022 Indian Journal of Pharmacology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Short Communication Swain, Trupti Rekha Goutam, Siddhartha Jena, Rabindra Kumar Rout, Niranjan Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience |
title | Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience |
title_full | Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience |
title_fullStr | Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience |
title_full_unstemmed | Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience |
title_short | Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience |
title_sort | analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: an eastern indian experience |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846910/ https://www.ncbi.nlm.nih.gov/pubmed/36537404 http://dx.doi.org/10.4103/ijp.ijp_844_21 |
work_keys_str_mv | AT swaintruptirekha analysisofadversedrugreactionsofimatinibinchronicmyeloidleukemiapatientsaneasternindianexperience AT goutamsiddhartha analysisofadversedrugreactionsofimatinibinchronicmyeloidleukemiapatientsaneasternindianexperience AT jenarabindrakumar analysisofadversedrugreactionsofimatinibinchronicmyeloidleukemiapatientsaneasternindianexperience AT routniranjan analysisofadversedrugreactionsofimatinibinchronicmyeloidleukemiapatientsaneasternindianexperience |